Hemophilia: How To Please Payers And Secure Market Share

Pharma companies are bringing forward innovative products that are set to shake up the hemophilia market – but convincing payers that they have substantial benefits over the current standards of care will be a challenge. Real-world data and early conversations with payers will be key, new research has found.

SC1703_Hemophilia._1200x675

The hemophilia market is expecting an influx of new products currently at the later stages of clinical development, including gene therapies, that will pile pressure on payers looking to contain costs. To secure market access, it will be critical for companies with entirely novel hemophilia therapies, as well as those providing incremental treatment benefits, to start conversations with payers as soon as possible. Care should also be taken over the design of clinical trials in order to maximize a new product's attractiveness.

New research published by Datamonitor Healthcare shows that payers are likely to favor therapies that substantially reduce the frequency of...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Rare Diseases

More from Scrip